# MITHRIDATE (NCT04116502)

> MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04116502
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: University of Birmingham
- Conditions: Polycythemia Vera
- Interventions: Ruxolitinib; Hydroxycarbamide; Interferon-Alpha
- Enrollment: 586
- Primary outcome: Event Free Survival (EFS)

## Commentary we found

- YouTube: 4
- Podcasts: 4
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mithridate-nct04116502

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04116502", "email": "<work email>"}; the inbox owner confirms by the emailed link.